Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.
about
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patientsCyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patientsHigh-dose chemotherapy for children and young adults with stage IV rhabdomyosarcomaCyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patientsChildren's Oncology Group's 2013 blueprint for research: Soft tissue sarcomasMultidisciplinary management of soft tissue sarcomaThe surgical management of paediatric bladder and prostate rhabdomyosarcomaPatterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma CommitteeRhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studiesComputed tomography and magnetic resonance imaging observations of rhabdomyosarcoma in the head and neckNeoplasms associated with germline and somatic NF1 gene mutationsImaging findings in craniofacial childhood rhabdomyosarcoma.Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's OncRelevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.Pediatric soft tissue sarcomas.Local therapy for rhabdomyosarcoma of the hands and feet: is amputation necessary? A report from the Children's Oncology Group.Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from thTumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology GroupRhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group.Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.Inhibition of metastasis of rhabdomyosarcoma by a novel neutralizing antibody to CXC chemokine receptor-4.Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects.Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.Imaging findings in noncraniofacial childhood rhabdomyosarcoma.Two Cases of Adolescents with Paratesticular Rhabdomyosarcoma Inadequately Treated: The Problem of Referral.A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups.Embryonal rhabdomyosarcoma: A rare oral tumor.Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment.Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups.Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: a report from the Children's Oncology GroupEarly response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.Prognostic role of tumor size in childhood cancer.Selecting multimodal therapy for rhabdomyosarcoma.Pharmacotherapy for pediatric soft-tissue sarcomas.Soft tissue sarcomas in children.What is the evidence for radical surgery in the management of localized embryonal bladder/prostate rhabdomyosarcoma?The challenge of access to care for soft tissue sarcomas bridging pediatric and adult age: the Italian pediatric oncology view.
P2860
Q24186938-C042DD30-1460-4C31-ABB1-0F49E0E5410BQ24202196-65F1170B-F8CD-426A-8B44-48250053F0DAQ24235604-DD1F655C-E534-4EC3-9128-F4ECB42702EAQ24240032-71FC2BBE-D122-430F-96BE-F4908F548418Q26825000-D8B1A39E-8929-412B-886E-F34753C4CEACQ26825028-189BBAAF-A778-4377-811D-DE99BF6363F4Q27015190-3C514CA9-3082-45C8-BF3B-926145245234Q33396263-3312DE69-67AD-4357-BB8C-A7907265E2D0Q33559468-16CFC15D-36DB-47D8-80A9-9962C5F877A3Q33778354-FECBF0B6-EFFD-455C-9383-262D55C15F2AQ34125947-5AB0ECA3-9E11-4EF4-8B03-825F9818F7E3Q34176966-34BD34D3-83FE-4FE5-8591-3F70AA22A716Q34402527-F1A13BFA-5611-4AA8-B93D-31DCE32206F9Q34589401-4EE364C6-42D2-47D7-A2F2-E5B58AFE9CAFQ34754962-F84538DF-50E3-43E6-95B2-2C42B9F0A386Q34786004-5839EDA5-41A9-4DAC-B43D-DF9F9F469302Q34879307-C05E70B1-238C-417E-89CA-8A2FE55B92B5Q35051029-00DC43E2-51C5-4B51-AB1A-A59502ABBBB9Q35084182-6C100B46-2C4A-4A7F-88E8-E1EA73D82827Q35119012-FDC5DF7A-4E61-411A-9FFB-3865E191F223Q35214578-E26BA102-B4DC-4204-BD4B-7A332FE56E84Q35713242-A066AE99-8679-4D05-AACA-81440FC68ABAQ35792061-C968DA06-B6C8-4927-AE04-C873E1A2D421Q36022696-DE5FD485-66FF-48AC-BEF7-C560B9793F9FQ36284400-CE2D0CDF-D342-472B-96AA-1899A25A9461Q36632585-FA38F775-C671-4F69-9F70-7C95F120B8DFQ36753647-4DD4908C-9A9C-4D91-BA86-FFC536EE347FQ36813562-232AB684-B719-4D48-9DD5-0F9150C93B35Q37212341-0CBD620C-4273-4AF9-93E2-8F6BCB206D43Q37312094-CDDE2050-0FD1-43A9-A6F9-757ABA7CE065Q37323038-7D9E755E-6FC3-4277-A4F5-EA6EF653251FQ37404111-D9C5235F-D489-498A-ADC5-8F055B4E7925Q37478437-1C202443-02E3-4BAA-A1F2-7EBCE216A7D2Q37621398-D666AF8D-B207-4B4E-8A98-26BFED0BE4FCQ37650605-E0BE6397-FD88-4F98-927B-B1C600156515Q37782096-D3C5AADD-8C0E-4FE8-94B3-F54AD893F210Q37838445-C19A4A79-5F2A-4462-ACF8-BC5CBEAB90D3Q37936326-9D6E1CA0-A55A-45AD-BC21-8606FE5DEC62Q37979742-8E491496-1AE5-429D-AD54-EC462981B377Q37982451-C73C3B82-E68C-4B94-9709-9616D49ACD05
P2860
Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Treatment of nonmetastatic rha ...... alignant Mesenchymal Tumor 89.
@en
Treatment of nonmetastatic rha ...... alignant Mesenchymal Tumor 89.
@nl
type
label
Treatment of nonmetastatic rha ...... alignant Mesenchymal Tumor 89.
@en
Treatment of nonmetastatic rha ...... alignant Mesenchymal Tumor 89.
@nl
prefLabel
Treatment of nonmetastatic rha ...... alignant Mesenchymal Tumor 89.
@en
Treatment of nonmetastatic rha ...... alignant Mesenchymal Tumor 89.
@nl
P2093
P356
P1476
Treatment of nonmetastatic rha ...... alignant Mesenchymal Tumor 89.
@en
P2093
Adrian van Unnik
Caroline Ellershaw
David Spooner
Françoise Flamant
H Basil Marsden
Helene Martelli
Jean Louis Habrand
Jose Sanchez de Toledo
Marie Jose Terrier-Lacombe
P304
P356
10.1200/JCO.2005.08.130
P407
P577
2005-02-22T00:00:00Z